# US Point Of Care Glucose Testing Market > US Point of Care Glucose Testing Market Research Report: Size, Share, Trend Analysis By Product Type (Lancing Devices, Strips, Blood-Glucose Meter), By Applications (Type-1 Diabetes, Type-2 Diabetes) and By End Users (Hospitals, Clinics, Home Care Settings, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.1% - **2024:** $ 865.2 Million - **2025:** $ 909.33 Million - **2035:** $ 1,495.68 Million - **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Siemens Healthineers (DE), Dexcom Inc (US), Terumo Corporation (JP), Nova Biomedical (US), Ascensia Diabetes Care (DE) **Report ID:** MRFR/HC/14348-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-point-of-care-glucose-testing-market-15875 --- ## Market Summary ## **US Point of Care Glucose Testing Market Overview** As per MRFR analysis, the US Point of Care Glucose Testing Market Size was estimated at 764.11 (USD Million) in 2023. The US Point of Care Glucose Testing Market Industry is expected to grow from 803.07(USD Million) in 2024 to 1,389.19 (USD Million) by 2035. The US Point of Care Glucose Testing Market CAGR (growth rate) is expected to be around 5.108% during the forecast period (2025 - 2035). ### **Key US Point of Care Glucose Testing Market Trends Highlighted** The US Point of Care Glucose Testing Market is witnessing significant trends driven by the increasing prevalence of diabetes across the nation. As per the Centers for Disease Control and Prevention (CDC), millions of Americans are diagnosed with diabetes, which has heightened the need for accessible and efficient glucose monitoring solutions. Key market drivers include the rising demand for diabetes management tools, advances in technology, and the growing emphasis on preventive healthcare. Healthcare providers are looking for ways to streamline testing processes, which has led to innovations in testing devices that provide rapid results with minimal patient discomfort. Opportunities also exist for manufacturers to explore integration with mobile health applications, allowing for more comprehensive patient data management and real-time monitoring. Additionally, partnerships with home healthcare services can create avenues for distributing point-of-care testing devices in non-traditional settings, further increasing their accessibility. Recently, there has been a noticeable trend toward user-friendly devices that cater to a diverse range of populations, including elderly patients and individuals with limited health literacy. As more individuals seek to take control of their health, the demand for at-home and portable glucose testing devices is anticipated to grow.This trend indicates a broader shift toward patient-centered care, where empowering patients with real-time data plays a crucial role. Overall, the US Point of Care Glucose Testing Market is evolving rapidly, with advancements supporting not just the testing process but also the overall management of diabetes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Point of Care Glucose Testing Market Drivers** ### **Rising Diabetes Prevalence** The increasing prevalence of diabetes in the United States is a significant driver for the US Point of Care Glucose Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, had diabetes in 2020. This alarming increase showcases a serious health crisis that necessitates constant glucose monitoring, which propels the demand for point of care glucose testing devices.Leading companies like Abbott Laboratories and Roche Diagnostics are responding to this surge by enhancing their product offerings and investing in technology for more accurate and user-friendly glucose meters. As the population ages and lifestyle diseases become more common, the number of diabetic patients is projected to rise, driving further growth in the glucose testing market. This trend is expected to increase the market's valuation significantly over the next decade. ### **Technological Advancements in Diagnostic Devices** Advancements in technology are revolutionizing the US Point of Care Glucose Testing Market Industry. The integration of smartphone connectivity, cloud-based data storage, and artificial intelligence are facilitating easier glucose monitoring and management. A report by the National Institutes of Health (NIH) suggests that digital health technologies can improve patient outcomes and compliance rates significantly. Prominent market players such as Dexcom and Johnson & Johnson are at the forefront of this innovation, introducing devices that provide real-time data and remote monitoring capabilities.These advancements not only enhance patient engagement but also improve overall clinical decision-making, considerably escalating the demand for advanced testing systems in the US. ### **Increased Demand for Home Healthcare Solutions** The growing preference for home healthcare solutions among patients is another critical driver for the US Point of Care Glucose Testing Market Industry. The COVID-19 pandemic has shifted patient behaviors significantly, with more individuals opting for remote monitoring to minimize hospital visits. A study published by the American Hospital Association indicates that there was a 20% increase in home health care services utilization from April to July 2020.Companies like LifeScan and Ascensia Diabetes Care are capitalizing on this trend by providing easy-to-use, portable glucose testing devices, ensuring that patients can manage their diabetes effectively from home. This shift not only enhances the quality of life for patients but also fosters a growing market for at-home healthcare products. ## **US Point of Care Glucose Testing Market Segment Insights** ### **Point of Care Glucose Testing Market Product Type Insights** The US Point of Care Glucose Testing Market is robustly categorized into various product types, including Lancing Devices, Strips, and Blood-Glucose Meters, each playing a vital role in diabetes management. Lancing Devices are essential tools that enable individuals to obtain blood samples painlessly, facilitating regular monitoring of glucose levels. Their convenience and user-friendly design contribute significantly to patient adherence to testing protocols. Strips, another critical component, are used in tandem with Blood-Glucose Meters to provide accurate glucose readings from blood samples.The innovation within this segment focuses on enhancing precision and reducing the time required for results, which is crucial for effective diabetes management. Blood-Glucose Meters serve as the primary interface for individuals with diabetes, offering the capability to display glucose readings and trends over time. Their advancement in technology, including features like connectivity to mobile applications and cloud storage, empowers diabetics to track their health more efficiently and make informed decisions about their diet and medication.The growing prevalence of diabetes in the US, alongside an increasing awareness and focus on preventive healthcare, drives demand across these product types. Market growth is further fueled by innovations such as smart glucose meters and continuous monitoring systems that promote proactive health management. The US Point of Care Glucose Testing Market segmentation reflects the ongoing evolution in diabetes care, where convenience and accuracy remain paramount, thereby suggesting a bright outlook for these indispensable product types. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Point of Care Glucose Testing Market Application Insights** The Application segment of the US Point of Care Glucose Testing Market is primarily focused on the management of diabetes, particularly Type-1 and Type-2 Diabetes, which are critical health issues in the United States. The growing prevalence of these diabetes types drives innovative solutions in glucose monitoring, facilitating timely and accurate readings. Type-1 Diabetes, often diagnosed in children and young adults, requires continuous management, which enhances the demand for advanced Point of Care testing solutions. Conversely, Type-2 Diabetes, more common among adults, is influenced by lifestyle factors, thereby necessitating regular glucose monitoring for effective disease management.The importance of educational initiatives and healthcare accessibility in the US further underscores the significance of this segmentconsumers increasingly seek easy-to-use glucose monitoring devices that can integrate seamlessly into their daily routines, making management more manageable. Consequently, the application of these testing technologies in clinical settings and home environments is expanding, reflecting the growing awareness of diabetes management among healthcare providers and patients alike. The US Point of Care Glucose Testing Market data reveals a tendency toward developing portable devices, emphasizing the convenience and real-time capabilities needed in diabetes healthcare strategies.Overall, advancements in technology and the rising focus on early diagnosis and personalized care significantly bolster the potential of this market segment. ### **Point of Care Glucose Testing Market End User Insights** The US Point of Care Glucose Testing Market presents a diverse array of end users, which play critical roles in the overall healthcare landscape. Hospitals traditionally serve as major settings for glucose monitoring, offering rapid test results crucial for immediate patient care. Clinics also contribute significantly, catering to the growing demand for diabetic patient management and routine check-ups, thus enhancing accessibility to glucose testing. Home care settings have emerged notably, driven by an increasing trend towards home healthcare solutions, allowing patients to manage their diabetes conveniently.This shift is supported by technological advancements and an aging population requiring continuous glucose monitoring. Other end users encompass a variety of healthcare environments, each playing unique roles in enabling effective glucose management. With the rise in diabetes prevalence in the US, the segmentation within the US Point of Care Glucose Testing Market reflects not only the importance of these settings but also the increasing demand for personalized healthcare, further emphasizing the need for efficient and accessible glucose testing solutions. ## **US Point of Care Glucose Testing Market Key Players and Competitive Insights** The US Point of Care Glucose Testing Market is characterized by a rapidly evolving landscape driven by technological advancements, patient-centered healthcare approaches, and an increasing prevalence of diabetes. This market comprises various devices and technologies designed to provide instant blood glucose testing at the point of care. Competitors in this space continuously strive to innovate by introducing new products that offer improved accuracy, faster results, and user-friendly interfaces. As the demand for quick and effective diabetes management solutions grows, companies are leveraging strategic partnerships, investments in research and development, and aggressive marketing strategies to enhance their market presence and capture a broader segment of the consumer base. Nova Biomedical has established a significant presence in the US Point of Care Glucose Testing Market, thanks to its comprehensive portfolio of glucose monitoring devices known for their accuracy and reliability. The company’s strength lies in its commitment to innovation, continuously developing advanced technologies that enhance the efficiency of glucose testing. Nova Biomedical's devices cater to various settings, including hospitals and private practices, making them versatile options for healthcare professionals. Their focus on user-centric design ensures that these devices are easy to operate, providing healthcare providers with rapid and precise results that are essential for effective patient management. Furthermore, Nova Biomedical maintains a strong customer support system, which is crucial in building trust and loyalty among healthcare practitioners. Roche Diagnostics has a firm foothold in the Point of Care Glucose Testing Market within the US, offering a diverse range of products and services tailored for efficient diabetes care. The company's key offerings include accurate blood glucose meters and diagnostic kits designed to facilitate seamless patient testing. Roche Diagnostics is known for its commitment to research and development, which enables them to introduce cutting-edge testing technologies that set industry standards. The company's strengths lie in its extensive distribution network and established relationships within the healthcare community, which enhance its market presence. Roche Diagnostics has also pursued strategic mergers and acquisitions to expand its capabilities and enrich its product lineup, thereby reinforcing its position in the US market while addressing the increasing needs of diabetes management among patients and healthcare providers. ### **Key Companies in the US Point of Care Glucose Testing Market Include** ## **US Point of Care Glucose Testing Market Industry Developments** Recent developments in the US Point of Care Glucose Testing Market have shown steady growth, propelled by innovations and increasing demand for rapid testing solutions. In August 2023, Abbott Laboratories announced the launch of a new version of its Freestyle Libre system, aimed at enhancing user experience and providing real-time glucose monitoring for patients. Meanwhile, Roche Diagnostics unveiled advancements in their Accu-Chek line, focusing on improved accuracy and ease of use. In terms of mergers and acquisitions, a notable move was Medtronic's acquisition of Mazor Robotics in September 2022, which is expected to bolster their diabetes management portfolio. The demand for seamless technology integration in diabetes management has led to collaborations, such as Dexcom partnering with Ascensia Diabetes Care for enhanced data management solutions. Furthermore, the market is seeing significant investments, with Becton Dickinson and Company committing to research and development to innovate their testing devices. This ongoing emphasis on technological improvement is likely shaping the landscape of the Point of Care Glucose Testing Market in the US, contributing to its rapid evolution and enhancing patient care efficacy. ## **US Point of Care Glucose Testing Market Segmentation Insights** ### **Point of Care Glucose Testing Market Product Type Outlook** ### **Point of Care Glucose Testing Market Application Outlook** ### **Point of Care Glucose Testing Market End User Outlook** ## Market Drivers ### Rising Prevalence of Diabetes The increasing prevalence of diabetes in the US is a primary driver for the point of-care-glucose-testing market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million Americans, or 10.5% of the population, have diabetes. This growing patient population necessitates more accessible and efficient glucose monitoring solutions. As healthcare providers seek to improve patient outcomes, the demand for point-of-care testing devices is likely to rise. These devices enable rapid glucose level assessments, facilitating timely clinical decisions. Furthermore, the trend towards personalized medicine emphasizes the need for continuous glucose monitoring, which could further propel the market. The point-of-care-glucose-testing market is thus positioned to expand significantly as healthcare systems adapt to the increasing burden of diabetes. ### Supportive Reimbursement Policies Supportive reimbursement policies are playing a crucial role in the growth of the point-of-care-glucose-testing market. Insurance coverage for point-of-care testing devices is becoming more prevalent, which encourages healthcare providers to adopt these technologies. The Centers for Medicare & Medicaid Services (CMS) has recognized the importance of glucose monitoring in managing diabetes, leading to favorable reimbursement rates for point-of-care testing. This financial support reduces the burden on patients and healthcare providers, making it easier to implement these testing solutions. As reimbursement policies continue to evolve, they are likely to further stimulate the point-of-care-glucose-testing market, ensuring that more patients have access to essential monitoring tools. ### Increased Focus on Preventive Healthcare The shift towards preventive healthcare in the US is influencing the point-of-care-glucose-testing market. With rising healthcare costs and a growing emphasis on early disease detection, healthcare providers are increasingly adopting point-of-care testing solutions. These devices allow for immediate glucose level assessments, enabling timely interventions that can prevent complications associated with diabetes. The American Diabetes Association advocates for regular monitoring, which aligns with the preventive healthcare model. As a result, the point-of-care-glucose-testing market is expected to experience growth, driven by the need for efficient and effective monitoring solutions. The convenience and speed of these tests are appealing to both patients and healthcare providers, potentially leading to increased adoption rates. ### Growing Demand for Home Healthcare Solutions The growing demand for home healthcare solutions is significantly influencing the point-of-care-glucose-testing market. As patients increasingly prefer to manage their health from home, the need for convenient and reliable glucose testing devices has surged. This trend is driven by the desire for autonomy in health management and the convenience of at-home testing. The point-of-care-glucose-testing market is responding to this demand by offering user-friendly devices that allow patients to monitor their glucose levels without frequent visits to healthcare facilities. Additionally, the aging population in the US, which often requires ongoing glucose monitoring, is likely to further drive this trend. As home healthcare continues to gain traction, the point-of-care-glucose-testing market is expected to expand, catering to the needs of patients seeking accessible monitoring solutions. ### Technological Innovations in Testing Devices Technological innovations are significantly impacting the point-of-care-glucose-testing market. Advances in biosensor technology, microfluidics, and connectivity features are enhancing the accuracy and usability of glucose testing devices. For instance, the integration of smartphone applications with testing devices allows for real-time data tracking and analysis, which is appealing to tech-savvy consumers. The market is witnessing the introduction of non-invasive glucose monitoring technologies, which could revolutionize patient experiences. As these innovations continue to emerge, they are likely to attract investment and drive competition within the market. The point-of-care-glucose-testing market stands to benefit from these advancements, as they align with the growing demand for user-friendly and efficient healthcare solutions. ## Future Outlook The [Point Of Care Glucose Testing Market](https://www.marketresearchfuture.com/reports/point-of-care-glucose-testing-market-12264) is projected to grow at a 5.1% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for rapid testing solutions. **New opportunities:** - Development of integrated mobile health applications for real-time glucose monitoring. - - Expansion of point-of-care testing in pharmacies and retail clinics. - Partnerships with telehealth platforms to enhance remote patient management. By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility. ## Segment Insights ### By Type: Blood-Glucose Meter (Largest) vs. Lancing Devices and Strips (Fastest-Growing) In the US point of-care-glucose-testing market, the Blood-Glucose Meter commands the largest share, indicating its established presence and critical role in diabetes management. Lancing Devices and Strips, while not as dominant, are seeing an increasing adoption rate among consumers, highlighting a shift towards more comprehensive monitoring solutions. This distribution showcases the varying preferences of users in managing their health effectively. Recent trends indicate a robust growth trajectory for Lancing Devices and Strips, propelled by technological advancements that enhance user experience and provide more accurate readings. Additionally, the rising prevalence of diabetes drives demand for efficient monitoring tools, making this segment the fastest-growing area within the US point of-care-glucose-testing market. Companies are increasingly focusing on innovation and convenience to capture the emerging market segment. Blood-Glucose Meter (Dominant) vs. Lancing Devices and Strips (Emerging) The Blood-Glucose Meter is a dominant player in the US point of-care-glucose-testing market, known for its reliability and widespread usage among patients requiring daily monitoring. This meter leverages advanced technology to provide accurate readings swiftly, making it essential for effective diabetes management. Conversely, Lancing Devices and Strips represent the emerging segment, characterized by a growing preference for integrated solutions that offer ease of use and enhanced comfort. Consumers are increasingly inclined towards lancing devices that minimize pain and optimize sample collection, reflecting a shift in the market landscape. The ongoing innovations and user-friendly designs in this segment are expected to reshape consumer choices, creating a more balanced competitive environment. ### By Application: Type-2 Diabetes (Largest) vs. Type-1 Diabetes (Fastest-Growing) In the US point of-care-glucose-testing market, Type-2 Diabetes accounts for a substantial share, reflecting a higher prevalence and greater awareness among patients and healthcare providers. The market segmentation indicates that Type-2 Diabetes testing solutions dominate sales and usage, driven by the increasing incidence rates and the emphasis on early detection and management strategies. Conversely, Type-1 Diabetes, although smaller in market share, shows promising adoption rates as more technologically advanced testing devices become available. The growth trends within this segment are significantly influenced by the rising number of diagnosed cases of both types of diabetes. Growing healthcare initiatives focused on comprehensive diabetes management, coupled with innovations in glucose testing technology, position Type-1 Diabetes as the fastest-growing segment. This growth is further propelled by increased consumer demand for home healthcare solutions and real-time health monitoring, resulting in a dynamic shift in the market landscape. Application: Type-2 Diabetes (Dominant) vs. Type-1 Diabetes (Emerging) Type-2 Diabetes testing solutions remain dominant in the US point of-care-glucose-testing market due to their widespread utilization, driven by a larger patient population and ongoing awareness campaigns. These solutions are characterized by their user-friendly features and integration with mobile health applications, facilitating better patient engagement and compliance in management practices. On the other hand, Type-1 Diabetes represents an emerging segment with rapid growth potential. Innovations such as continuous glucose monitors and automated insulin delivery systems offer enhanced patient convenience and improved accuracy, capturing the interest of both patients and healthcare providers. As technological advancements continue to evolve, the shift towards personalized medicine is expected to further expand the market presence of Type-1 Diabetes testing solutions. ### By End User: Hospitals and Clinics (Largest) vs. Home Care Settings (Fastest-Growing) In the US point of-care-glucose-testing market, the distribution of end-user segments reveals that hospitals and clinics command the largest share due to their established infrastructure and higher patient throughput. This segment benefits from the increasing demand for rapid diagnostic solutions in clinical environments, enhancing patient care and workflow efficiency. Conversely, home care settings are emerging as the fastest-growing segment, driven by the rising prevalence of diabetes and the growing preference for patient-centric care models. Innovative technologies and devices that facilitate self-testing are significantly boosting this segment's expansion, as patients seek greater control over their health management from the comfort of their homes. Hospitals and Clinics (Dominant) vs. Home Care Settings (Emerging) Hospitals and clinics represent the dominant end-user segment in the US point of-care-glucose-testing market, offering advanced diagnostic capabilities and immediate access to medical expertise. These facilities are equipped with sophisticated testing technologies, enabling rapid glucose assessments that improve patient outcomes. On the other hand, home care settings are rapidly becoming an emerging segment, fueled by technological advancements that support remote monitoring and self-testing. Patients increasingly prefer the convenience of performing tests in their own space, facilitating better adherence to diabetes management. This shift is not only making healthcare more accessible but is also fostering innovations in testing devices tailored specifically for home use. ## Competitive Benchmarking The point-of-care glucose testing market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of diabetes. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Dexcom Inc (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Abbott Laboratories (US) focuses on expanding its product portfolio with cutting-edge continuous glucose monitoring systems, while Roche Diagnostics (CH) emphasizes the integration of digital health solutions to improve patient outcomes. Dexcom Inc (US) is particularly noted for its advancements in real-time glucose monitoring technology, which positions it favorably in a market that increasingly values immediate data access and user-friendly interfaces.The competitive structure of the market appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce lead times and enhance responsiveness to market demands. This strategy not only mitigates supply chain disruptions but also aligns with the growing consumer preference for locally sourced products. The collective influence of these key players shapes a competitive environment where innovation and operational efficiency are paramount. In October Abbott Laboratories (US) announced a strategic partnership with a leading telehealth provider to integrate remote monitoring capabilities into its glucose testing solutions. This move is likely to enhance patient engagement and adherence to treatment protocols, reflecting a broader trend towards digital health integration. By combining telehealth with glucose monitoring, Abbott aims to provide a more comprehensive care model that could significantly improve patient outcomes and satisfaction. In September Roche Diagnostics (CH) launched a new cloud-based platform designed to facilitate data sharing between healthcare providers and patients. This initiative underscores Roche's commitment to digital transformation, enabling real-time data access and analytics that can inform treatment decisions. The strategic importance of this platform lies in its potential to enhance collaboration among healthcare stakeholders, ultimately leading to improved diabetes management. In August Dexcom Inc (US) unveiled an innovative algorithm that enhances the accuracy of its continuous glucose monitoring systems. This development is crucial as it addresses the growing demand for precision in diabetes management. By improving the reliability of glucose readings, Dexcom strengthens its competitive edge, appealing to both healthcare professionals and patients who prioritize accuracy in their treatment regimens. As of November the competitive trends in the point-of-care glucose testing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and robust supply chain reliability. This shift suggests that companies that prioritize innovation and adaptability will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments Recent developments in the US Point of Care Glucose Testing Market have shown steady growth, propelled by innovations and increasing demand for rapid testing solutions. In August 2023, Abbott Laboratories announced the launch of a new version of its Freestyle Libre system, aimed at enhancing user experience and providing real-time glucose monitoring for patients. Meanwhile, Roche Diagnostics unveiled advancements in their Accu-Chek line, focusing on improved accuracy and ease of use. In terms of mergers and acquisitions, a notable move was Medtronic's acquisition of Mazor Robotics in September 2022, which is expected to bolster their diabetes management portfolio. The demand for seamless technology integration in diabetes management has led to collaborations, such as Dexcom partnering with Ascensia Diabetes Care for enhanced data management solutions. Furthermore, the market is seeing significant investments, with Becton Dickinson and Company committing to research and development to innovate their testing devices. This ongoing emphasis on technological improvement is likely shaping the landscape of the [Point of Care Glucose Testing Market](https://www.marketresearchfuture.com/press-release/point-of-care-glucose-testing-market)in the US, contributing to its rapid evolution and enhancing patient care efficacy. ## Report Scope | MARKET SIZE 2024 | 865.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 909.33(USD Million) | | MARKET SIZE 2035 | 1495.68(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.1% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Siemens Healthineers (DE), Dexcom Inc (US), Terumo Corporation (JP), Nova Biomedical (US), Ascensia Diabetes Care (DE) | | Segments Covered | Type, Application, End User | | Key Market Opportunities | Integration of advanced digital health technologies enhances patient engagement in the point of-care-glucose-testing market. | | Key Market Dynamics | Technological advancements drive innovation in point-of-care glucose testing, enhancing accuracy and user convenience. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current market valuation of the US point-of-care glucose testing market?** A: The market valuation was $865.2 Million in 2024. **Q: What is the projected market valuation for the US point-of-care glucose testing market by 2035?** A: The projected valuation for 2035 is $1495.68 Million. **Q: What is the expected CAGR for the US point-of-care glucose testing market during the forecast period 2025 - 2035?** A: The expected CAGR is 5.1% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the US point-of-care glucose testing market?** A: Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Siemens Healthineers, Dexcom Inc, Terumo Corporation, Nova Biomedical, and Ascensia Diabetes Care. **Q: What are the main segments of the US point-of-care glucose testing market?** A: The main segments include Type, Application, and End User. **Q: What was the market size for Blood-Glucose Meters in 2024?** A: The market size for Blood-Glucose Meters was $565.2 Million in 2024. **Q: What is the projected market size for Lancing Devices and Strips by 2035?** A: The projected market size for Lancing Devices and Strips is expected to reach $500 Million by 2035. **Q: How does the market size for Type-1 Diabetes compare to Type-2 Diabetes in 2024?** A: In 2024, the market size for Type-1 Diabetes was $300 Million, while Type-2 Diabetes was $565.2 Million. **Q: What is the expected market size for Home Care Settings in 2035?** A: The expected market size for Home Care Settings is projected to be $600 Million by 2035. **Q: What was the market size for hospitals and clinics in 2024?** A: The market size for hospitals and clinics was $400 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-point-of-care-glucose-testing-market-15875*